A meta-analysis of studies of treatments for feline urine spraying by Mills, Daniel et al.
A Meta-Analysis of Studies of Treatments for Feline Urine
Spraying
Daniel S. Mills1*, Sarah E. Redgate1, Gary M. Landsberg2
1Animal Behaviour, Cognition and Welfare Group, Department of Biological Sciences, University of Lincoln, Lincoln, United Kingdom, 2North Toronto Animal Clinic,
Thornhill, Ontario, Canada
Abstract
Feline urine spraying inside the home is a common problem behaviour that owners seek advice for from veterinarians.
Individual trials relating to a variety of interventions produce variable results, and to date, no consensus on the value of
different treatments has emerged. This study therefore aimed to meta-analyse, current data from appropriate published
clinical trials that evaluate treatments for feline urine spraying. Inclusion and exclusion criteria for study selection were
predefined and methodological quality was assessed by two independent reviewers. Ten studies in nine publications that
either evaluated pharmacotherapy or pheromonatherapy (the use of a synthetic analogue of the F3 facial fraction in the cat)
were suitable for analysis. There was a significant (P,0.001) association between the use of any intervention and the
number of cats that ceased or reduced urine spraying by at least 90%. Analysis by intervention type indicated that
fluoxetine, clomipramine and pheromonatherapy may each assist in managing urine spraying beyond a placebo based
intervention. This is the first time meta-analytical techniques have been used and reported to evaluate the efficacy of
interventions used in veterinary behavioural medicine, and it has established confidence in the value of both conventional
treatments (pharmacotherapy) and a more recently developed treatment modality (pheromonatherapy) as an adjunct to
the management of this problem. It is suggested that future research into treatment efficacy for this problem uses the
benchmark standard of randomised, controlled trials lasting for at least 8 weeks, with the outcome criteria of cessation of
feline urine spraying or reduction by at least 90%.
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Introduction
Urine spraying forms a normal part of the cat’s behavioural
repertoire and can broadly be categorized as either sexual
(associated with reproductive function) or reactional (associated
with threats to resources) marking [1]. It is shown by both sexes, all
breeds and occurs irrespective of neutering, with approximately
10% of neutered males and 5% of spayed females exhibiting the
behaviour [1,2,3].
The behavioural sequence observed may vary subtly between
cats. In general, the cat will turn its back on the area of choice,
raise the tail and arch the back, then spray a variable quantity of
urine onto a vertical surface, whilst spraying the tail may also
quiver [4]. Vertical surfaces in the house are commonly sprayed
areas, often when they are near access points or windows. Owners
also report that targets include objects on the floor such as boxes or
bags and electrical items including plug sockets and household
appliances.
The number of areas sprayed differs between individuals with
some cats limiting spraying to one place, for instance a door frame
while others spray in multiple sites around the home. The
frequency of spraying episodes varies between households ranging
to in excess of 63 sprays a week [2,5,6]. The behaviour frequently
becomes a problem for the owner or carer and in extreme cases
may be the sole reason for relinquishment [7,8]. Data from
veterinary referrals to registered ‘‘Pet Behaviour Counsellors’’
show that urine spraying is one of the most frequently recognised
behaviour problems for which cat owners seek advice [9].
Feline lower urinary tract disorders have been associated with
the development of spraying and many behavioural and
environmental factors have also been implicated [6,10]. The
number of cats living in the household and the frequency of inter
cat aggression have been identified as risk factors, as have
environmental triggers such as a substantial changes in the
household, changes in routine or presence of neighbouring cats
[2,11,12].
Traditional management of the problem has included neutering
and or treatment with progestins [13], although the latter are no
longer generally recommended due to their side effects. Current
strategies advocate cleaning regimes for the urine and behavioural
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modification to remove any specific triggers alongside specific
psychopharmacological and non-pharmacological interventions
such as use of the feline facial pheromone fraction in the
environment [14]. Suggested psychopharmacological treatments
include benzodiazepines, azapirones, tricyclic antidepressants and
selective serotonin reuptake inhibitors [1,15,16,17,18,19].
To date a small number of randomised control trials and one-
group, uncontrolled trials have been carried out to evaluate the
effectiveness of intervention on the control of urine spraying. The
evidence indicates that none of the currently available interven-
tions are successful in completely resolving the behaviour in all
spraying cats, for this reason treatment outcome is often defined in
terms of number of cats that cease spraying and / or reduce
spraying beyond a certain rate. For example, Pryor et al., [18])
defines success as cessation or a 90% reduction of signs whereas,
Mills and Mills [6] report numbers that cease and numbers that
reduce.
This report aims to synthesize the current data from published
clinical trials that evaluate treatments for feline urine spraying. A
meta-analytical technique is used to evaluate peer reviewed studies
with appropriate data in order to discern the influence that non-
behavioural intervention methods have on the incidence of either
the cessation of urine spraying or its reduction.
Materials and Methods
Ethics Statement
This project was approved by the University of Lincoln local
ethics committee. A review protocol was not preregistered.
Search methods
Published reports of clinical trials evaluating an intervention for
feline urine spraying were collected through a comprehensive
search of three electronic databases ISI Web of Knowledge,
Ingenta Connect and Science Direct and one web search engine
Google Scholar. The search terms used were: Urine spraying,
Urine marking, Cat, Feline, Behaviour/Behavior. For the
databases the terms were entered into the topic section (ISI Web
of Knowledge) or through an advanced search and terms were
entered into the title, abstract, keywords section (Ingenta Connect
and Science Direct), without a publication date restriction.
Databases were accessed on the 25th April and 1st May 2009. In
addition, the references of all identified studies were inspected for
additional studies.
Study selection
Inclusion and exclusion criteria for study selection were
predefined, with some selected specifically to minimise the risk
of bias. All studies met the following inclusion criteria (1) the study
was published as a peer reviewed publication; (2) the study
provided sufficient information to extract representative data. We
excluded studies for the following reasons (1) cats were showing
sexual and not reactional spraying; (2) case studies; (3) follow up
studies (4) brief reporting of materials and methods (5) cats
showing horizontal urination.
All papers analysed were classified according to their level of
evidence and risk of bias as defined by the Centre for Evidence
Based Medicine, Oxford, UK [20]. Two reviewers (SR and GL)
independently rated the studies, rating results were compared, and
where differences were noted, they were discussed and reconciled.
Definition of a successful treatment outcome. The
definition of a successful treatment outcome varied between
studies and included, the number of cats that ceased or reduced
spraying by 90% [18,21] or the number of cats that ceased [2,6].
In addition, to the numbers that cease a proportion of studies also
reported the number of cats that reduced spraying relative to
baseline [2,5,6]. To compare all studies the number of cats that
either ceased or reduced spraying by at least 90% was used as a
primary outcome measure as it described the tightest criterion for
success among studies. However, as not all the cats ceased or
reduced spraying by at least 90% a secondary outcome measure
was formulated of the number of cats that reduce spraying from
baseline levels.
Data Analysis
Data were extracted from all published studies; in addition,
unpublished raw data were available from one study by the paper
author (D Mills). When full subject data were presented in tabular
format these data were used to extract the required information.
Missing data were taken into account when reporting total sample
sizes.
Meta-analysis is a statistical procedure for combining data from
multiple studies in order to identify a common effect of the
treatment.
Data were analyzed using Comprehensive Meta-analysis
Software version 2 (Biostat, Englewood, NJ, USA).
The potential heterogeneity among studies was tested using a
Cochran test. In case of evidence of significant heterogeneity a
random effects model was used. Alternatively, a fixed effects model
was used when heterogeneity was not evident [22].
The possible influence of publication bias was evaluated by
means of a funnel plot where log-transformed odds ratios were
plotted against standard errors.
Estimation of placebo effect. In order to allow us to include
studies without placebo control and assess if these studies were
biased compared to those with a placebo control, a placebo effect
was estimated. The placebo effect was evaluated on randomized
controlled trials with a negative control. The global placebo effect
was calculated with events rate and its 95% confidence interval.
Analysis of the primary outcome. A notable caveat for this
analysis is the lack of studies with a placebo control group. In an
attempt to remedy this we used the information from two studies
with a placebo group [6,18] to generate an estimate of the effect size
of the placebo. This effect size was then used in an analysis of all
studies in order to compare interventions. Event rate for the treated
group of each study was compared against the estimated event rate
for the placebo group. These events rates were calculated in order to
produce a 95% odds ratio and its 95% confidence interval for each
study and for the global treatment effect.
The odds ratios compare the likelihood that the subject exposed
to the treatment will develop the outcome compared to a subject
that is not exposed.
Further separate analyses were then performed to determine the
influence of intervention type (fluoxetine, clomipramine and
synthetic feline facial pheromone F3).
Analysis of the secondary outcome. It was expected that
the majority of studies which simply reported a reduction in
spraying would have used the synthetic feline facial pheromone
F3. Therefore an additional predefined analysis was performed to
examine the influence of pheromones on a reduction in urine
spraying in comparison to baseline levels. Event rate and its
confidence interval were calculated for the treated group and
compared to the baseline values.
Results
The search identified 20 papers including conference proceed-
ings that reported data from 24 studies. Studies evaluating
Meta-Analysis: Treatment for Feline Urine Spraying
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pharmacotherapy and pheromonatherapy were included. A total
of 15 studies were excluded from the analysis for reasons detailed
in Table 1. Hart et al. [21] evaluated two active treatments in their
study, for the purpose of this analysis each treatment group was
considered separately. This left a total of 10 studies for analysis
(see: Diagram S1).
Two types of trial design were noted, randomised control trials
(RCT) and one group (uncontrolled) pre-post design. Four RCT’s
were identified; this group included one study with a positive
control [21] and three studies of treatment against a placebo
control group [6,18,19]. One of the RCT studies did not provide
raw data for the placebo control group [19] thus only the data
from the treated group could be used in the analysis. Four studies
were open-label one-group pre and post designs [2,5,32,33]. One
study included a within subjects control group [1].
Study quality varied (Table 2), four out of the ten studies were
double blind randomised controlled trials and thus rated as 1b
[6,18,19,21]; although two of the studies from this group had
results with wide confidence intervals [6,21], and 1b level of
evidence is typically considered to be a randomised controlled
study with a narrow confidence interval [20]. The remaining six
studies were open label trials, with the exception of Dehasse [1]
and therefore were classed as providing level 4 evidence
(equivalent to case series and poor quality cohort and case control
studies, and so with a higher risk of bias).
Types of participants
Cats of both sexes neutered and entire were included, notably all
of the studies evaluating pharmacological interventions only
recruited neutered cats with the exception of one study [1]. Breed
was not always stated so it can not be assumed that all breeds are
represented. The age of the participant was not always stated, when
reported cats ranged in age between 4 months and 16.5 years.
Home environment. The home environment of the feline
participants varied both within and between studies. All cats were
studied in their home environment, this was usually the household
although, Ogata and Takeuchi [5] reported that two cats from
their study population spent a proportion of time in a cage. In all
reports the cats were managed either as indoor only cats or indoor
cats with some degree of outdoor access.
Cats were recruited from single and multi-cat households, with
the exception of Dehasse [1] all authors reported that they
recruited from multi-cat households. The number of cats living
within each multi-cat household varied, for example, Frank et al.
[2] reported a range of 2–14 cats per household with a mean of 4.5
and a median of 3. A proportion of studies only recruited cats from
multi-cat households with # 4 cats [18,21,33].
Description of spraying behaviour. All studies reported
that cats showed the classic signs described by Dehasse [1] of a cat
spraying a vertical surface. Not all authors noted the duration of the
problem behaviour, when it was reported the minimum duration
Table 1. Excluded studies and main reason for exclusion from the analysis.
STUDY REFERENCE EXCLUSION CRITERION
Schwartz S [23] Case study
Pageat P [24] Cats showing sexual spraying
Pageat P [25], Pageat P and Tessier Y [26], Pageat P and Tessier Y [27], Seksel K.
and Lindeman MJ [17], White JC and Mills DS [28], Kroll T and Houpt KA [29]
Incomplete description of the materials and methods, with raw data or only
descriptive statistics. (conference abstracts), preventing further evaluation
Mills DS and White JC [30] Follow up study
Marder AR [31] Not peer reviewed
Hart BL [13] Cooper L and Hart BL [15], Hart BL, Eckstein RA, Powell KL
and Dodman NH [16]
Included cats showing horizontal spraying
doi:10.1371/journal.pone.0018448.t001
Table 2. Information from each study including type of intervention, trial design, blinding and agreed level of evidence according
to the Oxford Centre for Evidence-based Medicine Levels of Evidence.
STUDY INTERVENTION DESIGN
BLINDING (SELF
REPORT)
BLINDING
(INVESTIGATOR)
LEVEL OF
EVIDENCE
Frank et al. [2] F3 pheromone spray One-group pre and post design No No 4
Hunthausen [32] F3 pheromone spray One-group pre and post design No No 4
Mills and Mills [6] F3 pheromone diffuser RCT Yes Yes (pers. comm..) 1b -
Ogata and Takeuchi [5] F3 pheromone spray One-group pre and post design No No 4
Dehasse [1] Clomipramine One-group, placebo vs. treatment Yes No 4
Hart et al. [21] Clomipramine RCT active control Yes Yes 1b -
Hart et al. [21] Fluoxetine RCT active control Yes Yes 1b
King et al. [19] Clomipramine RCT Yes Yes 1b
Landsberg and Wilson [33] Clomipramine One-group pre and post design No No 4
Pryor et al. [18] Fluoxetine RCT Yes Yes 1b
RCT (randomised, controlled trial), ‘‘-’’ denotes a single result with a wide Confidence Interval.
doi:10.1371/journal.pone.0018448.t002
Meta-Analysis: Treatment for Feline Urine Spraying
PLoS ONE | www.plosone.org 3 April 2011 | Volume 6 | Issue 4 | e18448
prior to entering a study was 5 days and the maximumwas 10 years.
The studies evaluating pheromonatherapy appeared more likely to
report on the duration of the behaviour. With the exception of
Hunthausen [32] all authors that stated they recruited frommulticat
households ensured that the spraying cat was identified.
Veterinary screening. Cats entering the study were either
veterinary referrals or screened for underlying physiological
complications that could influence spraying behaviour or
interfere with the evaluation of the treatment. Cats were
enrolled with evidence of feline lower urinary tract disease and
other concurrent medical disorders (see Frank et al. [2] and
Landsberg and Wilson [33] for examples).
Behavioural advice offered during the study. The
tendency to offer behavioural advice differed between studies.
Frank et al [2]; Landsberg and Wilson [33]; Mills and Mills [6];
Ogata and Takeuchi [5] stated that no specific behavioural advice
was offered whereas, Hart et al. [21]; King et al.[19]; Pryor et al.
[18] advised owners to employ basic environmental management
such as ensuring urine marks were cleaned with an appropriate
enzyme based cleaner and keeping litter boxes clean.
Duration of intervention period. In the main, the
pharmaceutical interventions were administered for a longer
duration than the pheromone interventions. The intervention
period for pheromone treatment was consistently reported after 28
days in comparison to a mean of 67 days for the pharmacotherapy
with a minimum of 7 days [1] and a maximum of 112 days [21].
Placebo effect
Two randomized controlled studies included a negative control
group (placebo) [6,18]. Pryor et al. [18] examined the influence of
fluoxetine and reported that 0/8 cats in the placebo group ceased
or reduced spraying by at least 90%. Mills and Mills [6] evaluated
the use of a synthetic feline facial pheromone F3 diffuser, and
noted that in the placebo group 4/12 cats ceased or reduced
spraying by at least 90%. (Table 3). Heterogeneity was not
significant between the two studies (Cochran Q test P.0.10), so a
global effect was estimated.
The global estimated placebo effect was of 0.20 (20% of cats
ceased or reduced urine spraying by at least 90%) with a 95%
confidence interval of [0.03; 0.38]. The global placebo effect
generated was then used in subsequent comparisons.
Primary outcome: All studies; Cessation or reduction of at
least 90%
When all studies were analysed the effect of intervention was
significant compared to placebo (p,0.0001). The rate of cessation
or reduction in urine spraying of at least 90% was significantly
improved by 3.16 in the case of intervention compared to placebo
(Odds ratio = 3.16, 95% confidence limits [1.94–5.14]) (Table 4
and Figure 1). Heterogeneity between studies was not significant
(P.0.10).
There was no evidence of publication bias from visual
inspection of the funnel plot (Figure 2).
Primary outcome: Analysis by intervention type:
fluoxetine
Two studies were included in the analysis that evaluated
fluoxetine. Hart et al., [21] evaluated fluoxetine use over a 16 week
period and Pryor et al. [18] over 8 weeks. Heterogeneity between
Table 3. Summary data for the estimated placebo effect.
Study name Number of events Total Effective Event rate (%) with 95% CI
Pryor et al. [18] 0 8
Mills and Mills [6] 4 12
Global estimate 4 20 0.20 (20%) [0.03–0.38]
Heterogeneity: P.0.10.
doi:10.1371/journal.pone.0018448.t003
Table 4. Primary outcome All studies; cessation and reduction of at least 90%.
Study name Intervention Total N Event rate
Odds ratio with 95% CI and significance of
global estimate
Frank et al. [2] F3 Pheromone spray 17 0.18 0.86 [0.16–4.51]
Hunthausen [32] F3 Pheromone spray 54 0.33 2.00 [0.58–6.86]
Ogata & Takeuchi [5] F3 Pheromone spray 36 0.36 2.26 [0.62–8.21]
Mills and Mills [6] F3 Pheromone diffuser 10 0.20 1.00 [0.15–6.67]
Dehasse [1] Clomipramine 26 0.35 2.12 [0.54–8.26]
Landsberg & Wilson [33] Clomipramine 25 0.68 8.50 [2.14–33.81]
King et al. [19] Clomipramine 18 0.61 6.29 [1.48–26.76]
Hart et al. [21] Clomipramine 6 0.33 2.00 [0.27–15.08]
Hart et al. [21] Fluoxetine 16 0.69 8.80 [1.92–40.34]
Pryor et al. [18] Fluoxetine 9 1.00 69.67 [3.37–1440.21]
Global estimate 3.16 [1.94–5.14] P,0.0001
Heterogeneity: P.0.10.
doi:10.1371/journal.pone.0018448.t004
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studies was not significant (Cochran Q test P.0.10) thus the fixed
effects model was used. The number of cats that ceased or reduced
urine spraying by at least 90% was significantly (P,0.001)
associated with the use of fluoxetine (OR 13.36, 95% CI [3.43–
52.06]); (Table 5 and figure 3).
Primary outcome: Analysis by intervention type:
clomipramine
Four studies evaluated clomipramine use [1,19,21,33]. There was
no heterogeneity between studies (Cochran Q test P.0.10). There
was a significant (P,0.001) association between clomipramine use
and the number of cats that cease or reduce urine spraying by at
least 90% (OR 4.23, 95% CI [2.00–8.93]): (Table 6 and figure 4).
The duration of the treatment period varied between the studies
(Dehasse [1] 7 days; Hart et al. [21], 16 weeks; Landsberg &
Wilson [33], 4 weeks and King et al., [19], 12 weeks).
Primary outcome: Analysis by intervention type:
Synthetic feline facial pheromone F3
Four studies were included in the analysis that evaluated the use
of the synthetic feline facial pheromone F3 over a four week
treatment period [2,5,6,32]. Heterogeneity was not evidenced
Figure 1. Effect of each study and global effect (OR ± CI 95%) – log scale (x axis).
doi:10.1371/journal.pone.0018448.g001
Figure 2. Funnel plot of the association between the estimated effect size and its standard error in individual studies.
doi:10.1371/journal.pone.0018448.g002
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between studies (Cochran Q test P.0.10). The analysis showed
that the number of cats that ceased or reduced urine spraying by at
least 90% was not significant (P = 0.21) but in favour of the
synthetic feline facial pheromone F3 (OR=1.60) with a 95%
confidence interval of [0.77–3.30]: (Table 7 and figure 5).
Secondary outcome: Synthetic feline facial pheromone
F3 and Reduction in spraying
Three studies were included in the analysis of the effect of four
weeks’ of pheromonatherapy on urine spraying (Table 8). No
heterogeneity was reported between the studies (Cochran Q test
P.0.10) and a fixed effect model was adopted. There was a
significant association (P,0.05) between use of synthetic feline
facial pheromone F3 and a reduction in urine sprays, there was an
overall event rate of 0.92, 95% CI [0.85–0.98] (Table 8).
Follow up
Six out of ten studies collected data on urine spraying after
initial treatment. Duration of the follow up period varied between
3 days [1] and five months [33]. Two studies evaluated
pheromone use and reported no statistical evidence of a relapse
rate, four weeks after withdrawal of the 4 week-treatment [2,5].
The remaining four studies all evaluated pharmacotherapy use.
Dehasse [1] evaluated the use of clomipramine and reported no
evidence of relapse after a period of 3 days after 7 days treatment.
After fluoxetine withdrawal for either 4 [18] or 8 weeks [21] there
was an increase in spraying rate in comparison to the treatment
phase for some cats, with others returning to baseline levels. A
more typical follow up period of 5 months was reported by
Landsberg and Wilson [33]. They noted that after four week’s of
clomipramine treatment that only one quarter of the cats did not
require medication to control the spraying.
Discussion
Ten studies were identified as suitable to include in this review
based on pre-determined inclusion criteria. However, the quality
of evidence available was variable. Half of the studies were double
blinded, randomised controlled trials whereas the remaining
studies were open label, one-group pre and post designs.
Randomised controlled trials with adequate allocation of treat-
ments and masking are considered to provide high quality
evidence as bias is minimised. In contrast, open label designs
without a control group are generally considered to provide lower
confidence in the quality of evidence as they are potentially open
to bias due to pre-conceived ideas or misconceptions. To minimise
any inherent risk from bias, appropriately masked and rando-
mised, controlled trials are advocated, but they are not always
feasible or available, especially in the early phases of development
Figure 3. Effect of fluoxetine studies and global effect (OR ± CI 95%) – log scale (x axis).
doi:10.1371/journal.pone.0018448.g003
Table 5. Primary outcome (Fluoxetine studies); cessation and reduction of at least 90%.
Study name Intervention Total N Event rate
Odds ratio with 95% CI and significance of global
estimate
Hart et al. [15] Fluoxetine 16 0.69 8.80 [1.92–40.34]
Pryor et al. [18] Fluoxetine 9 1 69.67 [3.37–1440.21]
Global estimate 13.36 [3.43–52.06] P,0.0001
Heterogeneity: P.0.10.
doi:10.1371/journal.pone.0018448.t005
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of a product. In general, perceived quality of study design was not
associated with intervention type and heterogeneity was generally
low, being minimal within the pheromone treatment group
(Table 8) even though only one of the studies in this group was
a randomised double blinded, controlled trial [6].
Overall, the results suggest that adjunctive interventions beyond
general management advice and placebo significantly improved
the probability that urine spraying either ceased or reduced by at
least 90%. The sustained use of fluoxetine had the largest reported
effect. However, only two relatively small studies contributed to
this result, with one of these, Pryor et al. [18] reporting a complete
resolution or at least a 90% reduction in behavioural signs in all
nine cats within the treated group. Further evaluation of this
treatment is required to establish whether the results can be
replicated with larger sample sizes. The evidence presented for
clomipramine was more variable with only two out of the four
studies [19,33] clearly different to placebo (Figure 1). The result
seems not to relate clearly with daily dosage as Dehasse [1]
administered the highest dose of 5mg per cat per day whereas
King et al.[19] administered the lowest dose at 0.25–0.5mg/kg/d.
This may reflect variation in the populations of cats or disparities
between study designs such as, an interaction between dosage
versus duration of treatment. Within this treatment group, it is
worth noting that the largest reported effect size was from the only
open label trial [33] this may suggest that knowledge of the
treatment influences reliability of the outcome number of spraying
marks reported by owners.
The synthetic feline facial pheromone F3 presented as a spray
or a diffuser had, on average, little effect on the probability of
cessation or at least a 90% reduction in behavioural signs after 4
weeks only. In contrast, a large, effect was detected when
considering the number of cats that reduced spraying by week
four of treatment in comparison to baseline. This suggests that
pheromones do reduce the overall incidence of spraying after only
four weeks. In comparison, the pharmacological studies consis-
tently emphasise their effect after 8–16 weeks in the case of
fluoxetine and up to 16 weeks in the case of clomipramine, there is
therefore a need for longer term studies reporting on pheromo-
natherapy efficacy on durations equivalent to those used to
establish efficacy for pharmaceutical treatments using comparable
criteria, such as the ‘‘at least 90% reduction threshold’’ which is
reported here. Results from such studies would allow more direct
comparison with pharmacological agents. Larger field studies
comparing pheromonatherapy with pharmacotherapy over the
Figure 4. Effect of clomipramine studies and global effect (OR ± CI 95%) – log scale (x axis).
doi:10.1371/journal.pone.0018448.g004
Table 6. Primary outcome (Clomipramine studies); cessation and reduction of at least 90%.
Study name Intervention Total N Event rate
Odds ratio with 95% CI and significance of
global estimate
Dehasse [1] Clomipramine 26 0.35 2.12 [0.54–8.26]
Landsberg & Wilson [33] Clomipramine 25 0.68 8.50 [2.14–33.81]
King et al. [19] Clomipramine 18 0.61 6.29 [1.48–26.76]
Hart et al. [21] Clomipramine 6 0.33 2.00 [0.27–15.08]
Global estimate 4.23 [2.00–8.93] P,0.0001
Heterogeneity: P.0.10.
doi:10.1371/journal.pone.0018448.t006
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more typically prolonged period used in pharmacological studies
would also be of particular value in highlighting any compliance
differences between the two strategies in practice, since the oral
dosing required for effective medication is often considered to be
a barrier to the use of medication and favour the use of
pheromonatherapy. However there are currently no studies to
support or refute this suggestion in this incidence.
Recurrence rate is likely to be determined by individual factors
within a given case and duration since treatment cessation. In the
latter case it is important to distinguish between relapses associated
with ongoing treatment or the withdrawal of treatment before
complete resolution of the original problem. In addition, animals
may become exposed to new stressors which instigate the problem
again (technically, these should not be considered relapses as they
are a new incidence of the problem). Further evaluation of
recurrence rate is required for all interventions and this review
highlights some inconsistencies between studies. For example, the
duration of time between treatment cessation and subsequent
follow up was highly variable (between 3 days –20 weeks). If it is
accepted that three days can not be considered normal for
monitoring follow up [1] duration of follow up varied between 4
and 20 weeks.
Frank et al [2] and Ogata and Takeuchi [5] both reported an
initial reduction or cessation in spraying behaviour after pheromone
treatment. The latter authors also independently note that four
weeks after treatment withdrawal that a return to baseline levels of
the problem was not evident. This result concurs with a longer term
study [30] that reported on spraying behaviour 10 months after a
five week treatment period with a pheromone spray [28]. Forty
three owners were contacted, none of the owners had been using the
treatment on a daily basis and thirteen owners still used the
intervention intermittently. Although 77% of cases were considered
to be under adequate control from the owner’s perspective only 6
cats (14%) were not spraying at all at this time, with 27 cats (63%)
spraying at a lower rate than at the start of the study. This raises
important questions about owner compliance and how success
should be evaluated, since an owner maymake a trade off between a
certain acceptable rate of spraying and the effort required to reduce
it. Therefore, controlled laboratory studies may be important in
determining the objective potential of these interventions, rather
than their field efficacy. With every treatment, an increase in
spraying frequency was noted for a majority of cats [18,28], and in
one report for all cats [21] after the treatment intervention ceased
and this deserves further investigation, although in at least one
Table 7. Primary outcome (Synthetic feline facial pheromone F3 studies); cessation and reduction of at least 90%.
Study name Intervention Total N Event rate
Odds ratio with 95% CI and significance of
global estimate
Frank et al. [2] F3 Pheromone spray 17 0.18 0.86 [0.16–4.51]
Hunthausen [32] F3 Pheromone spray 54 0.33 2.00 [0.58–6.86]
Ogata & Takeuchi [5] F3 Pheromone spray 36 0.36 2.26 [0.62–8.21]
Mills and Mills [6] F3 Pheromone diffuser 10 0.20 1.00 [0.15–6.67]
Global estimate 1.60 [0.77–3.30] P =0.21
Heterogeneity: P.0.10.
doi:10.1371/journal.pone.0018448.t007
Figure 5. Effect of synthetic facial pheromone F3 studies and global effect (OR ± CI 95%) – log scale (x axis).
doi:10.1371/journal.pone.0018448.g005
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report [28] the majority of cats were spraying at a lower level
compared to baseline 10 months after treatment.
When comparing studies it was evident that certain differences
existed between the feline populations sampled and this tended to
correlate with the type of intervention under evaluation, three
notable discrepancies are discussed.
Five out of the 6 pharmacological studies only sampled neutered
cats, whereas non-neutered cats were included in the pheromone
studies. How much this impacted on the individual studies results
is unclear given that all cats sampled were classed as reactional
sprayers rather than sexual sprayers [1]. However, it is often
recommended as a first line of treatment to neuter cats that are
persistently urine spraying [13].
Overall, the maximum number of cats living in each household
was greater for the pheromone studies with a range of between 1–
31 cats per household. The risk of inter cat aggression within the
household is likely to increase in line with an increasing feline
population due to limited space and access to resources [34,35].
Frank et al. [2] and Ogata and Takeuchi [5] both note that
pheromone treatment success was reduced within multi-cat
households with notable inter-cat aggression. The impact of this
on pharmacological interventions remains unknown.
Simple environmental management can reduce the weekly
spraying rate [12]. However, only owners taking part in certain
trials evaluating the pharmacological interventions were asked to
implement management changes whilst administering the inter-
vention under evaluation. Owners were not asked to implement
changes whilst using the synthetic feline facial pheromone F3.
Thus the effect of pheromones reported here may be a
conservative estimate.
The studies evaluating pharmacological interventions selected
their subjects on the basis of more stringent inclusion criteria. These
criteria will have ensured a more uniform study population and
together with the additional environmental interventions made may
have inflated the relative effect reported here. It would be of benefit
for future studies that seek to evaluate interventions to use
comparable stringent criteria to maximise the specificity of effect.
The studies evaluating pheromonatherapy were more likely to
report on the history of the spraying behaviour. However, no
associations were found between treatment success and either
duration of the problem or number of cats in the household or age
of cats [28]. It would be interesting to ascertain whether this also
applies to pharmacological interventions.
We recognise that there are limitations associated with the
conclusions from the summary effect presented here, given that it
was necessary to generate an estimated placebo effect size, but we
believe this does at least provide a common benchmark for
comparison and the basis for more objective evaluation of
treatment. To enable a more comprehensive meta-analysis in the
future it is recommended that studies should review trial design
and methods in line with these recommendations: (1) trial design
should be a blinded RCT; (2) full subject data should be
presented or an estimate of effect size for both the treated and
placebo groups; (3) the outcome measure should be clearly
established and include the number of cats that cease or reduce
spraying by at least 90% and also the numbers that reduce by a
given amount.
In conclusion, there is good evidence that both pharmacological
and pheromonal interventions provide added value for the
reduction of urine spraying in the cat. It is worth noting that the
most extensive treatment programme described, i.e. the one
involving a triple line intervention consisting of psychopharma-
cology (fluoxetine), environmental modification and a cleaning
regime for the longest period of time appears to be the most
effective treatment documented to date. This emphasises the
potential need for a comprehensive treatment programme for
maximum effect. Further studies are required to dissect out the
relative importance of each element and their possible synergies
with other treatments (e.g the use of pheromonatherapy) in
addition. In addition further masked, controlled trials with stricter
study population inclusion criteria for at least eight weeks are also
required especially in relation to the effect of F3 facial fraction
pheromone on feline urine spraying in the household.
Supporting Information
Diagram S1 PRISMA Flowchart.
(DOC)
Acknowledgments
We would like to thank Bruno Combes for his helpful statistical support.
Author Contributions
Conceived and designed the experiments: DSM GML. Analyzed the data:
SER DSM GML. Wrote the paper: SER DSM GML.
References
1. Dehasse J (1997) Feline urine spraying. Applied Animal Behaviour Science 52:
365–371.
2. Frank DF, Erb HN, Houpt KA (1999) Urine spraying in cats: presence of
concurrent disease and effects of pheromone treatment. Applied Animal
Behaviour Science 61: 263–272.
3. Hart BL (1973) Effects of castration on hting, roaming and urine spraying in
adult male cats. Journal of the American Veterinary Medical Association 53:
331–344.
4. Bradshaw JWS (1992) The Behaviour of the Domestic Cat. Wallingford: CAB
International. 240 p.
Table 8. Secondary outcome.
Study name Number of events Total Effective
Event rate (%) with 95% CI and significance of global
estimate
Frank et al. [2] 15 17
Ogata and Takeuchi [5] 33 35
Mills and Mills [6] 9 10
Global Outcome 57 62 0.92 (92%) [0.85–0.98] P,0.05
Heterogeneity: P.0.10.
The influence of synthetic feline facial pheromone F3 (Feliway spray and Feliway diffuser): Number of cats that reduce spraying after treatment.
doi:10.1371/journal.pone.0018448.t008
Meta-Analysis: Treatment for Feline Urine Spraying
PLoS ONE | www.plosone.org 9 April 2011 | Volume 6 | Issue 4 | e18448
5. Ogata N, Takeuchi Y (2001) Clinical Trial of a Feliway Pheromone Analogue
for Feline Urine Marking. The Journal of Veterinary Medical Science 63:
157–161.
6. Mills DS, Mills CB (2001) Evaluation of a novel method for delivering a
synthetic analogue of feline facial pheromone to control urine spraying by cats.
The Veterinary Record 149: 197–199.
7. Patronek GJ, Glickman LT, Beck AM, McCabe GP, Ecker C (1996) Risk factors
for relinquishment of cats to an animal shelter. Journal of the American
Veterinary Association 209: 582–588.
8. New JC, Salman MD, King M, Scarlett JM, Kass PH, et al. (2000)
Characteristics of shelter-relinquished animals and their owners compared with
animals and their owners in U.S. pet-owning households. Journal of Applied
Animal Welfare Science 3: 179–201.
9. Association of Pet Behaviour Counsellors (2005) Annual Review of Cases.
Available: http://www.apbc.org.uk/data.htm. Accessed 2010 Mar 22.
10. Osbourne CA, Lulich JP, Ulrich LK, Bird KA (1996) Feline crystalluria.
Veterinary clinics of North America: Small Animal Practice 26: 369–391.
11. Horwitz DF (1997) Behavioural and environmental factors associated with
elimination behaviour problems in cats: a retrospective study. Applied Animal
Behaviour Science 52: 129–137.
12. Pryor PA, Hart BL, Bain MJ, Cliff KD (2001b) Causes of urine marking in cats
and effects of environmental management on frequency of marking. Journal of
the American Veterinary Medical Association 219: 1709–1713.
13. Hart BL (1980) Objectionable urine spraying and urine marking in cats:
evaluation of Progestin treatment in gonadectomized males and females. Journal
of the American Veterinary Medical Association 177: 529–533.
14. Neilson JC (2009) House Soiling by Cats. In: Horwitz DF, Mills DS, eds.
BSAVA Manual of Canine and Feline Behavioural Medicine (Second Edition).
Gloucester: British Small Animal Veterinary Association. pp 117–126.
15. Cooper L, Hart BL (1992) Comparison of diazepam with progestin for
effectiveness in suppression of urine spraying behavior in cats. Journal of the
American Veterinary Medical Association 200: 797–801.
16. Hart BL, Eckstein RA, Powell KL, Dodman NH (1993) Effectiveness of
buspirone on urine spraying and inappropriate urination in cats. Journal of the
American Veterinary Medical Association 203: 254–258.
17. Seksel K, Lindeman MJ (1998) Use of clomipramine in the treatment of anxiety-
related and obsessive-compulsive disorders in cats. Australian Veterinary Journal
76: 317–320.
18. Pryor PA, Hart BL, Cliff KD, Bain MJ (2001a) Effects of a selective serotonin
reuptake inhibitor on urine spraying behavior in cats. Journal of the American
Veterinary Medical Association 219: 1557–1561.
19. King, JN, Steffan J, Heath SE, Simpson BS, Crowell-Davis SL, et al. (2004)
Determination of the dosage of clomipramine for the treatment of urine spraying
in cats. Journal of the American Veterinary Medical Association 225: 881–887.
20. Phillips B, Ball C, Sackett D, Badenoch D, Straus S, et al. (2009) Oxford Centre
for Evidence-based Medicine Levels of Evidence. Available: http://www.cebm.
net/index.aspx?o=1025. Accessed 2011 Jun 30.
21. Hart BL, Cliff KD, Tynes VV, Bergman L (2005) Control of urine marking by
use of long-term treatment with fluoxetine or clomipramine in cats. Journal of
the American Veterinary Medical Association 226: 378–382.
22. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR (2009) Introduction to
Meta-Analysis. Chichester: John Wiley & Sons Ltd. 421 p.
23. Schwartz S (1999) Use of cyproheptadine to control urine spraying in a castrated
male domestic cat. Journal of the American Veterinary Medical Association 215:
501–502.
24. Pageat P (1997) Experimental evaluation of the efficacy of a synthetic analogue
of cats’ facial pheromones (Feliway) in inhibiting urine marking of sexual origin
in adult tom-cats. Journal of Veterinary Pharmacology and Therapeutics 20:
169.
25. Pageat P (1996) Functions and use of the facial pheromones in the treatment of
urine marking in the cat. Interest of a structural analogue. In: Johnston D,
Waner T, eds. XXIst Congress of the World Small Animal Veterinary
Association, Jerusalem, Israel, October 20th-23rd.
26. Pageat P, Tessier Y (1997a) The F3 facial pheromone (Feliway): a means to
inhibit sexually stimulated urine marking in cats. In: Proceedings of the Seventh
International European Association of Veterinary Pharmacology and Toxicol-
ogy Congress, Madrid, Spain, July 6th-10th.
27. Pageat P, Tessier Y (1997b) Usefulness of F3 Synthetic Pheromone (Feliway) in
Preventing Behaviour Problems in Cats during Holidays. In: Mills DS, Heath SE,
Harrington LJ, eds. Proceedings of the First International Conference on
Veterinary Behavioural Medicine, Birmingham, UK, April 1-2. Potters Bar:
Universities Federation for Animal Welfare. 231 p.
28. White JC, Mills DS (1997) Efficacy of Synthetic Feline Facial Pheromone (F3)
Analogue (Feliway) for the Treatment of Chronic Non-Sexual Urine Spraying by
the Domestic Cat. In: Mills DS, Heath SE, Harrington LJ, eds. Proceedings of
the First International Conference on Veterinary Behavioural Medicine,
Birmingham, UK, April 1-2. Potters Bar: Universities Federation for Animal
Welfare. 242 p.
29. Kroll T, Houpt KA (2001) A Comparison of Cyproheptadine and Clomipra-
mine for the Treatment of Spraying Cats. In: Overall KL, Mills DS, Heath SE,
Horwitz D, eds. Proceedings of the 3rd International Congress of Veterinary
Behavioural Medicine. Potters Bar: Universities Federation for Animal Welfare.
pp 184–185.
30. Mills DS, White JC (2000) Long-term follow up of the effect of a pheromone
therapy on feline spraying behaviour. The Veterinary Record 147: 476–747.
31. Marder AR (1991) Psychotropic drugs and behavioral therapy. Veterinary
Clinics of North America: Small Animal Practice 21: 329–342.
32. Hunthausen W (2000) Evaluating a feline facial pheromone analogue to control
urine spraying. Veterinary Medicine 95: 151–156.
33. Landsberg GM, Wilson AL (2005) Effects of clomipramine on cats presented for
urine marking. Journal of the American Animal Hospital Association 41: 3–11.
34. Borchelt P, Voith V (1996) Readings in Companion Animal Behavior: Trenton,
New Jersey: Veterinary Learning Systems. 276 p.
35. Levine E, Perry P, Scarlett J, Houpt KA (2005) Intercat aggression in households
following the introduction of a new cat. Applied Animal Behaviour Science 90:
325–336.
Meta-Analysis: Treatment for Feline Urine Spraying
PLoS ONE | www.plosone.org 10 April 2011 | Volume 6 | Issue 4 | e18448
